Debiopharm inks deal with INC Research
This article was originally published in Scrip
Executive Summary
The CRO INC Research has formed a strategic partnership with Swiss biopharmaceutical company Debiopharm, which will see the CRO manage a clinical study for Debio 0932, while both have agreed a framework for INC's collaboration on future trials.
You may also be interested in...
Hoops, hoopla, big ideas and diabetes
Perhaps only a man who inherited an enthusiasm for peptides could, without a trace of irony, cast diabetes drug development as the work of a pastry chef. But for David Solomon, the son of a peptide devotee, mixed metaphors and stretched comparisons are simply the spray thrown up by his unbridled enthusiasm for his chosen trade, that of basketball coach to GLP-1 receptor agonist developer Zealand Pharma.
How Dennis Gillings took a gamble and built a $3.7bn business
"How the hell will Glaxo need you? You've only got a few people, they've got about 50,000!"